Multicenter, open-label, phase 1 study of DSP-7888 Dosing Emulsion (DSP-7888) in patients with advanced malignancies

被引：0
|
作者：
Groves, Morris [2 ]
Hansen, Aaron [3 ]
Harb, Wael [4 ]
Curtis, Kelly [5 ]
Koga-Yamakawa, Erina [6 ]
Origuchi, Makoto [7 ]
Li, Zhonggai [7 ]
Iglesias, Jose [7 ]
Shaib, Walid [8 ]
Spira, Alexander [1 ]
机构：
[1] Virginia Canc Specialists, Fairfax, VA USA
[2] Texas Oncol Austin Midtown, Austin, TX USA
[3] UHN Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Horizon Oncol Res LLC, Lafayette, IN USA
[5] Syneos Hlth, Phoenix, AZ USA
[6] Sumitomo Dainippon Pharma Co Ltd, Cambridge, MA USA
[7] Boston Biomed Inc, Cambridge, MA USA
[8] Emory Univ, Atlanta, GA 30322 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P355
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma
    Carlo-Stella, Carmelo
    Zinzani, Pier Luigi Luigi
    Sureda, Anna
    Araujo, Luis Francisco
    Casasnovas, Olivier
    Carpio, Cecilia
    Yeh, Su-Peng
    Bouabdallah, Krimo
    Cartron, Guillaume
    Kim, Won Seog
    Cordoba, Raul
    Koh, Youngil
    Re, Alessandro
    Alves, Daniela
    Chamuleau, Martine E. D.
    Le Gouill, Steven
    Lopez-Guillermo, Armando
    Moreira, Maria Ilidia
    Van Der Poel, Marjolein W. M.
    Abbadessa, Giovanni
    Meng, Robin
    Ji, Ran
    Lepine, Lucie
    Saleem, Rao
    Ribrag, Vincent
    BLOOD, 2021, 138
  • [22] A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
    Carlo-Stella, Carmelo
    Zinzani, Pier Luigi
    Sureda, Anna
    Araujo, Luis
    Casasnovas, Olivier
    Carpio, Cecilia
    Yeh, Su-Peng
    Bouabdallah, Krimo
    Cartron, Guillaume
    Kim, Won Seog
    Cordoba, Raul
    Koh, Youngil
    Re, Alessandro
    Alves, Daniela
    Chamuleau, Martine
    Le Gouill, Steven
    Lopez-Guillermo, Armando
    Moreira, Ilidia
    van der Poel, Marjolein W. M.
    Abbadessa, Giovanni
    Meng, Robin
    Ji, Ran
    Lepine, Lucie
    Saleem, Rao
    Ribrag, Vincent
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (01) : 108 - 119
  • [23] A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
    Lin, Chia-Chi
    Garralda, Elena
    Schoeffski, Patrick
    Hong, David S.
    Siu, Lillian L.
    Martin, Miguel
    Maur, Michela
    Hui, Rina
    Soo, Ross A.
    Chiu, Joanne
    Zhang, Tian
    Ma, Brigette
    Kyi, Chrisann
    Tan, Daniel S. W.
    Cassier, Philippe A.
    Sarantopoulos, John
    Weickhardt, Andrew
    Carvajal, Richard D.
    Spratlin, Jennifer
    Esaki, Taito
    Rolland, Frederic
    Akerley, Wallace
    Deschler-Baier, Barbara
    Rispoli, Lawrence
    Samant, Tanay S.
    Chowdhury, Niladri Roy
    Gusenleitner, Daniel
    Kwak, Eunice L.
    Askoxylakis, Vasileios
    De Braud, Filippo
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [24] ARTACUS: AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RP1 IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH ADVANCED CUTANEOUS MALIGNANCIES
    Luke, Jason
    Migden, Michael
    Chai-Ho, Wanxing
    Bolotin, Diana
    Wise-Draper, Trisha
    Poklepovic, Andrew
    Laux, Douglas
    Kheterpal, Meenal
    Verschraegen, Claire
    Collichio, Frances
    Lutzky, Jose
    Daniels, Gregory
    Tsai, Katy
    Navia, Susan
    Castro, Henry
    Bommareddy, Praveen
    Pirzkall, Andrea
    Coffin, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A580 - A580
  • [25] Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET)
    Bechter, Oliver Edgar
    Unger, Nicole
    Borbath, Ivan
    Ricci, Sergio
    Hwang, Tsann-Long
    Park, Young Suk
    Tomasek, Jiri
    Raef, Hussein
    Laohavinij, Sudsawat
    JeanLouis, Lisa
    Panneerselvam, Ashok
    Saletan, Stephen
    Stergiopoulos, Sotirios G.
    Pavel, Marianne E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
    Richardson, Gary Edward
    Al-Rajabi, Raed
    Uprety, Dipesh
    Hamid, Anis
    Williamson, Stephen K.
    Baranda, Joaquina
    Mamdani, Hirva
    Lee, Ya-Li
    Li, Li
    Wang, Xingli
    Dong, Xunwei
    CANCERS, 2023, 15 (09)
  • [27] A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors
    Trarbach, T.
    Drevs, J.
    Strumberg, D.
    Gauler, T. C.
    Schneider, V.
    Eberhardt, W. E.
    Marotti, M.
    Puchalski, T. A.
    Swaisland, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study
    Brown, Jennifer
    Plummer, Ruth
    Bauer, Todd M.
    Anthony, Stephen
    Sarantopoulos, John
    De Vos, Filip
    White, Mike
    Schupp, Marco
    Ou, Ying
    Vaishampayan, Ulka
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2017, 6
  • [29] Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study
    Jennifer Brown
    Ruth Plummer
    Todd M. Bauer
    Stephen Anthony
    John Sarantopoulos
    Filip De Vos
    Mike White
    Marco Schupp
    Ying Ou
    Ulka Vaishampayan
    Experimental Hematology & Oncology, 6
  • [30] Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies
    Lê, H
    Swenerton, KD
    Elit, L
    Provencher, DM
    Stuart, GCE
    Le, T
    Lee, U
    Rodgers, A
    Pond, GR
    Hu, H
    Oza, AM
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (05) : 799 - 806
12345